Whalesbook: AI-Powered Stock Updates via WhatsApp

Stock Analysis

Corporate Announcements

30th Mar 26

Impact Rating: 6

Vineet Laboratories is closing its trading window for designated persons starting April 1, 2026. This closure will last until 48 hours after the declaration of its Q4 and annual financial results for the year ending March 31, 2026.

16th Feb 26

Impact Rating: -

No description available.

14th Feb 26

Impact Rating: 7

The company's Q3 FY26 unaudited standalone results indicate a revenue dip of 10.17% compared to the previous year, but a strong 112.14% increase in net profit driven by other factors.

14th Feb 26

Impact Rating: 7

Vineet Laboratories announced its unaudited standalone financial results for Q3 FY26. While Revenue from Operations declined by 10.16% YoY to ₹15.65 Cr, the company reported a significant 112.14% YoY jump in Net Profit to ₹0.85 Cr.

11th Feb 26

Impact Rating: -

No description available.

Peer Comparision

S.No.	Name	Current Price (Rs.)	Price to Earning	Market Capitalization (Rs.Cr.)	Dividend yield (%)	Net Profit latest quarter (Rs.Cr.)	YOY Quarterly profit growth (%)	Sales latest quarter (Rs.Cr.)	YOY Quarterly sales growth (%)	Return on capital employed (%)	Sales (Rs.Cr.)	OPM (%)	Profit after tax (Rs.Cr.)	Profit after tax latest quarter (Rs.Cr.)	Price to book value	Return on assets (%)	Debt to equity
1.	Sun Pharma.Inds.	1760.20	36.58	422330.94	0.91	3124.95	2.56	14478.31	8.93	20.21	54964.01	30.12	11543.96	3117.95	5.43	12.97	0.07
2.	Divi's Lab.	6642.50	70.96	176337.50	0.45	689.00	35.10	2715.00	16.12	20.44	10029.00	32.37	2485.00	689.00	11.44	13.53	0.01
3.	Torrent Pharma.	3936.80	61.50	133239.20	0.81	591.00	32.49	3302.00	14.30	27.05	12248.00	32.60	2166.53	600.17	15.77	13.26	0.33
4.	Cipla	1530.80	22.73	123653.62	0.85	1353.37	3.73	7589.44	7.64	22.72	28349.57	25.40	5441.14	1351.17	3.76	14.72	0.01
5.	Dr Reddy's Labs	1256.20	18.16	104846.27	0.64	1336.80	7.28	8828.30	9.83	22.69	34310.00	24.64	5772.20	1347.10	2.91	12.95	0.16
6.	Lupin	2149.70	22.71	98198.04	0.56	1484.83	73.34	7047.51	24.23	21.30	24750.69	27.25	4324.63	1477.92	5.00	12.41	0.32
7.	Zydus Lifesci.	931.05	18.63	93685.42	1.18	1238.60	40.92	6123.20	16.92	24.31	24493.90	31.10	5029.35	1283.60	3.70	14.64	0.38
8.	Vineet Laborator	34.63	–	66.51	0.00	0.40	121.86	17.42	-8.12	-27.95	57.04	-20.48	-16.71	0.40	4.68	-20.90	3.01
–	Median: 151 Co.	405.75	30.68	1679.94	0.11	12.57	11.71	152.64	10.58	14.89	574.01	15.93	43.84	13.49	3.11	8.56	0.22

Quarterly Results

Standalone figures in ₹ crores

	Dec 2022	Dec 2023	Dec 2024	Jun 2023	Jun 2024	Jun 2025	Mar 2023	Mar 2024	Mar 2025	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Sales	66.76	32.65	18.10	37.52	23.86	7.44	57.20	37.05	14.08	39.51	43.37	18.96	17.42
Expenses	64.81	33.29	22.23	37.26	24.65	7.13	51.39	33.63	25.12	43.52	39.20	19.27	14.24
Operating Profit	1.95	-0.64	-4.13	0.26	-0.79	0.31	5.81	3.42	-11.04	-4.01	4.17	-0.31	3.18
Other Income	0.00	0.01	0.03	0.03	0.37	0.02	0.03	0.41	1.38	0.00	0.01	0.20	0.01
Profit before tax	0.41	-2.34	-5.67	-1.28	-2.17	-0.91	4.85	1.44	-11.22	-5.32	2.55	-1.72	0.37
Tax %	-239.02%	-11.11%	0.53%	-2.34%	-1.84%	-4.40%	26.80%	-34.03%	-6.24%	-11.84%	4.71%	6.98%	-8.11%
Net Profit	1.39	-2.07	-5.71	-1.25	-2.13	-0.87	3.55	1.92	-10.53	-4.70	2.42	-1.83	0.40
EPS in Rs	0.72	-1.08	-2.97	-0.65	-1.11	-0.45	1.85	1.00	-5.48	-2.45	1.26	-0.95	0.21

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	0	243	191	212	151	75	57
Expenses	0	235	178	205	143	91	69
Operating Profit	-0	8	13	8	7	-16	-12
Other Income	0	0	0	0	0	2	1
Interest	0	3	2	3	5	4	5
Depreciation	0	2	2	2	3	2	3
Profit before tax	-0	4	9	2	0	-21	-17
Net Profit	-0	2	7	1	1	-20	-17
EPS in Rs	-0.11	0.93	3.46	0.65	0.54	-10.52	-8.69
Dividend Payout %	0%	0%	14%	0%	0%	0%	–

Balance Sheet

Standalone figures in ₹ crores

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	0.41	9	9	9	9	9	9
Reserves	-0	17	24	24	26	5	5
Borrowings	0	12	27	31	44	40	43
Other Liabilities	0	70	74	51	38	40	34
Total Liabilities	0	109	133	116	117	95	91
Fixed Assets	0	20	21	27	27	25	24
Gross Block	0.00	35.48	39.22	46.85	49.64	50.69	–
Accumulated Depreciation	0.00	15.82	17.83	20.21	22.73	25.23	–
CWIP	0	0	0	0	0	0	0
Investments	0	0	0	0	0	0	0
Other Assets	0	89	112	89	90	69	66
Total Assets	0	109	133	116	117	95	91

Cash Flows

Standalone Figures in ₹ Crores / Yearly

	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	27	8	-10	-7	11
Cash from Investing Activity	-8	-4	-7	-2	-3
Cash from Financing Activity	19	12	0	8	-8
Net Cash Flow	38	16	-16	-0	0

Ratios

Standalone Figures in ₹ Crores / Yearly

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	–	64	69	60	77	64
Inventory Days	–	73	109	98	158	260
Days Payable	–	114	161	74	103	175
Cash Conversion Cycle	–	23	17	84	131	150
Working Capital Days	–	14	-19	21	28	-37
ROCE %	–	34%	23%	9%	7%	-28%

Shareholding Pattern

Numbers in percentages

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	35.96%	38.66%	38.66%	38.66%	37.55%	37.50%	37.50%	36.07%	35.85%	35.85%	29.26%	15.89%
FIIs	0.00%	0.00%	0.00%	0.00%	0.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	–	–	–	–	–	–	–	–	–	–	–	–
Public	64.03%	61.35%	61.34%	61.34%	62.20%	62.50%	62.49%	63.93%	64.15%	64.15%	70.74%	84.11%

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Vineet Laboratories to Close Trading Window from April 1 for Q4 and FY Results

30th March 2026, 9:05 pm

Vineet Labs Publishes Q3 FY26 Results; Financial Updates Also from Athena Global, NCL Buildtek, Pennar Industries

16th February 2026, 6:07 pm

Vineet Laboratories Announces Q3 FY26 Standalone Results: Revenue Drops 10% YoY, PAT Surges 112% YoY

14th February 2026, 9:37 pm

Vineet Laboratories Announces Standalone Q3 Results: PAT Surges 112% YoY to ₹0.85 Cr Despite Revenue Dip

14th February 2026, 9:21 pm

Vineet Laboratories Ltd - 543298 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

11th February 2026, 10:59 pm

Published by Other Websites

External media mentions & references

Mega Corporate Actions Next Week: Rs 2.5 Dividend, Splits, Rights & More – Key Dates You CANNOT Miss!

20th December 2025, 8:40 am

Unlock Next Week: Stock Splits, Demergers, Dividends & More - Which Stocks Are Moving?

19th December 2025, 5:35 pm

Major Stock Alert: 8 Indian Companies Set for Big Moves Next Week with Dividends, Splits & Buybacks!

19th December 2025, 2:19 pm

Key Stocks in Focus for August 12 Trade Amid Earnings, Deals, and New Launches

12th August 2025, 8:15 am

Major Bulk and Block Deals Signal Active Investor Trading in Indian Equities

11th August 2025, 9:56 pm

News Articles

Editorial & research coverage

Major Stock Alert: 8 Indian Companies Set for Big Moves Next Week with Dividends, Splits & Buybacks!

19th December 2025, 2:19 pm

Documents

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication

29 Dec - Newspaper Advertisements published before the date of opening of the Rights Issue as required under Regulation 84(1) of SEBI (ICDR) Regulations, 2018.

Closure of Trading Window

27 Dec - Trading window closed Jan 1, 2026 until 48 hours after Q3 results (Dec 31, 2025).

Announcement under Regulation 30 (LODR)-Raising of Funds

20 Dec - Rights issue: 99,87,258 shares @₹30 raising ₹29.97 crore; record date Dec 23, 2025; opens Jan 1, 2026.

Intimation Of International Securities Identification Number ('ISIN') For The Rights Entitlements To Be Credited For The Purpose Of The Rights Issue

17 Dec - ISIN INE505Y20010 assigned for Vineet Laboratories rights entitlements; will be credited before issue opens.

Corporate Action-Intimation of Right issue

17 Dec - Rights issue of 99,87,258 shares at Rs.30 each raising Rs.29.96 crore; opens Jan 1, 2026; record date Dec 23, 2025.